IVF

Saipan IVF Announces Exclusive VIP Services for Chinese Clients, Expanding Presence in Chinese Market

Retrieved on: 
Tuesday, March 5, 2024

Saipan, United States--(Newsfile Corp. - March 5, 2024) - Saipan IVF, a leading provider of assisted reproductive technology services in the Pacific region, is proud to announce the launch of exclusive VIP services for Chinese Clients.

Key Points: 
  • Saipan, United States--(Newsfile Corp. - March 5, 2024) - Saipan IVF, a leading provider of assisted reproductive technology services in the Pacific region, is proud to announce the launch of exclusive VIP services for Chinese Clients.
  • This strategic initiative highlights Saipan IVF's commitment to expanding its presence in the Chinese market and offering more convenient and personalized medical services to Chinese clients.
  • Situated on the beautiful island of Saipan, Saipan IVF Center is an American-style reproductive medicine center that integrates clinical medical care with a humanistic approach.
  • With a customer-oriented focus, Saipan IVF provides high-quality medical services from the United States, boasting top reproductive doctors, embryologists, and professional nursing teams.

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Retrieved on: 
Wednesday, March 6, 2024

ATLANTA, March 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces the first commercial procedure using its FemaSeed intratubal insemination product.

Key Points: 
  • “FemaSeed presents an important advancement in women’s health with the availability of FemaSeed, a cost-effective and potentially safer alternative to other traditional infertility treatments,” said Femasys’ CEO Kathy Lee-Sepsick.
  • “This first commercial application of the technology marks a pivotal moment in reshaping female infertility management, particularly in light of the recent legal rulings on frozen embryos by the Alabama Supreme Court.
  • Engineered to precisely deliver sperm into the fallopian tube, the site of conception, FemaSeed enables reliable and safe fertilization.
  • Dr. Andrew Wagner, Women’s OB-GYN PC, Saginaw, Michigan, who completed the first in-office commercial procedure, stated, “This marks a pivotal moment for women pursuing a reliable, readily available frontline alternative for infertility.

Gattaca Genomics Appoints Dr. Tyl Taylor as New Director of Genetics Services

Retrieved on: 
Thursday, March 7, 2024

Florida, March 06, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics, a leading name in genetic services, appoints Dr. Tyl Taylor as its new Director of Genetics Services.

Key Points: 
  • Florida, March 06, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics, a leading name in genetic services, appoints Dr. Tyl Taylor as its new Director of Genetics Services.
  • Dr. Taylor brings a wealth of experience and expertise in the field, making him a valuable addition to the Gattaca team.
  • In his role as the Director of Genetics Services at Gattaca, Dr. Taylor is poised to lead the team towards new heights in genetic research and reproductive technologies.
  • We are confident that under his guidance, Gattaca will continue to drive advancements in genetic services," said Michael Carbonara, CEO of Gattaca Genetics.

Vytelle Expands Presence in Nebraska Region with the Opening of its 17th Global Laboratory, Ushering in a New Level of Accessibility to Hormone-Free in vitro Fertilization (IVF) for Cattle Producers

Retrieved on: 
Monday, March 4, 2024

This expansion further signifies Vytelle's commitment to providing innovative reproductive solutions and unparalleled access to hormone-free IVF for beef and dairy producers.

Key Points: 
  • This expansion further signifies Vytelle's commitment to providing innovative reproductive solutions and unparalleled access to hormone-free IVF for beef and dairy producers.
  • With its newest laboratory situated in Nebraska, a region known for elite cattle genetics and performance-focused herds, Vytelle continues to revolutionize the way livestock reproduction is managed.
  • The expansion will enable local producers to access Vytelle ADVANCE™, a breakthrough in vitro fertilization (IVF) technology, empowering them to further enhance their herds' genetic potential and overall productivity.
  • The Nebraska-based laboratory offers increased accessibility to modern reproduction technology and enables the possibility of fresh embryo transfers for producers in the region.

Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Retrieved on: 
Wednesday, February 28, 2024

ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today highlighted that its FemaSeed intratubal insemination product, a revolutionary approach to enhancing fertilization, is expected to serve as a first-line therapeutic option that is substantially lower cost with significantly less risk than assisted reproductive methods, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). FemaSeed has been designed to deliver sperm reliably and safely, directly into the fallopian tube where conception occurs.

Key Points: 
  • -- Femasys readies for the commercial launch of FemaSeed® in the U.S. amidst the uncertainty following the Alabama Supreme Court Ruling on how to handle embryos used for in vitro fertilization (IVF) --
    ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today highlighted that its FemaSeed intratubal insemination product, a revolutionary approach to enhancing fertilization, is expected to serve as a first-line therapeutic option that is substantially lower cost with significantly less risk than assisted reproductive methods, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
  • FemaSeed has been designed to deliver sperm reliably and safely, directly into the fallopian tube where conception occurs.
  • “Femasys remains committed to providing accessible and affordable options and the timing of FemaSeed’s launch is particularly relevant given the uncertainty following the Alabama Supreme Court ruling on February 16th.
  • Following our substantial cash infusion in the fourth quarter 2023, we are now funded into the second half of 2025 and on track to make FemaSeed, available later this year to women and their doctors, as a first-line treatment option that does not involve handling of embryos,” said Femasys’ CEO Kathy Lee-Sepsick.

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023

Retrieved on: 
Wednesday, February 28, 2024

Fabien de Ladonchamps, CEO, will remain in function during the notice period for the duration of the moratorium process and beyond, as needed.

Key Points: 
  • Fabien de Ladonchamps, CEO, will remain in function during the notice period for the duration of the moratorium process and beyond, as needed.
  • The moratorium limits the ability of ObsEva's creditors to enforce their claims against the company while it evaluates the possibility of a restructuring or orderly liquidation.
  • Therefore, we decided to inform SIX of the situation.
  • This may lead to a delisting.”

Leading Reproductive Expert Dr. Eva Schenkman Takes Helm as Director of Embryology Services at Gattaca Genomics

Retrieved on: 
Tuesday, February 27, 2024

Fort Lauderdale, Florida, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics proudly appoints renowned scientist, Dr. Eva Schenkman, as the Director of Embryology Services.

Key Points: 
  • Fort Lauderdale, Florida, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics proudly appoints renowned scientist, Dr. Eva Schenkman, as the Director of Embryology Services.
  • Dr. Schenkman's appointment as Director of Embryology Services signifies Gattaca Genomics' commitment to attracting top-tier talent in the field.
  • In her capacity as Director of Embryology Services, Dr. Schenkman will leverage her extensive experience in IVF laboratory management, andrology, and embryology to lead Gattaca Genomics in pioneering advancements in reproductive health.
  • Michael Carbonara, CEO of Gattaca Genomics says, "Dr. Eva Schenkman's appointment is a testament to Gattaca Genomics' commitment to excellence.

Ovation Fertility Welcomes Pradeep Warikoo, PhD, HCLD, ELD, CC (ABB), as Cincinnati Lab Director

Retrieved on: 
Tuesday, February 20, 2024

Nashville, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pradeep Warikoo, PhD, HCLD, ELD, CC (ABB), has joined the Ovation® Fertility team as laboratory director of Ovation Fertility Cincinnati, effective February 1, 2024.

Key Points: 
  • Nashville, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pradeep Warikoo, PhD, HCLD, ELD, CC (ABB), has joined the Ovation® Fertility team as laboratory director of Ovation Fertility Cincinnati, effective February 1, 2024.
  • Dr. Warikoo comes to Ovation from the Bethesda Fertility Center Reproductive Study Lab in Cincinnati, where he has served as scientific director for more than 25 years.
  • “Ovation’s expansion in the Cincinnati area involves a close partnership with our partner physicians at the Institute for Reproductive Health, which combined with Bethesda Fertility Center effective February 1,” says Conor Beardsley, President of Ovation Fertility.
  • He is board certified by the American Board of Bioanalysis as a High Complexity Laboratory Director, Embryology Laboratory Director and Clinical Consultant.

HRC Fertility Announces Dream Plus Embryo Banking Package

Retrieved on: 
Thursday, March 7, 2024

HRC Fertility (HRC), one of the largest and established providers of advanced fertility treatments, is proud to introduce its latest offering, the Dream Plus Embryo Banking package , in anticipation of National Infertility Awareness Week , April 21-27.

Key Points: 
  • HRC Fertility (HRC), one of the largest and established providers of advanced fertility treatments, is proud to introduce its latest offering, the Dream Plus Embryo Banking package , in anticipation of National Infertility Awareness Week , April 21-27.
  • “We are thrilled to launch the Dream Plus package, particularly as we head toward National Infertility Awareness Week,” said Sherif Hanna, CEO at HRC Fertility.
  • With the Dream Plus Embryo Banking package, we aim to alleviate some challenges associated with multiple stimulation cycles, especially for those with lower ovarian reserve or advanced reproductive age.”
    As part of the Dream Plus Embryo Banking package, patients will benefit from embryo freezing with one year of included storage, subject to limitations and exclusions.
  • To learn more about HRC Fertility and its Dream Plus Embryo Banking Package or book an appointment, please visit https://www.havingbabies.com/appointments/ .

SHE Media's Second Annual Co-Lab at SXSW® Elevating Leading Voices in Women's Health to the Mainstage

Retrieved on: 
Friday, March 8, 2024

AUSTIN, Texas, March 8, 2024 /PRNewswire/ -- Today, SHE Media, a mission-driven media company, announced its full agenda and latest speaker lineup for the Co-Lab: Whole Life Health at South by Southwest® (SXSW®). The highly anticipated activation, in its second year, will take place March 9, 10 and 11 in Downtown Austin at 206 E 4th St. Attendees will hear from experts, advocates, and thought leaders as they share both the science and stories of women's whole life health including the latest innovations and how technology is revolutionizing healthcare. Doors will open daily at 9am and close at 5pm with panel discussions and fireside chats programmed throughout the day. Full agenda details and updates can be found here.

Key Points: 
  • Doors will open daily at 9am and close at 5pm with panel discussions and fireside chats programmed throughout the day.
  • The Co-Lab at SXSW marks the one-year anniversary of launching Flow Space , SHE Media's proprietary digital and live media platform providing content, community, and commerce in service of women's health.
  • Learn how we can better care for our hearts, including how symptoms differ in women, preventative measures and innovations that can reduce risk.
  • plusOne® Sexual Wellness in Full Bloom | Attendees can celebrate sexual wellness by stopping by the plusOne® flower cart to receive a tote and Rose Arouser.